Fermenta Biotech Limited , a leading manufacturer of Vitamin D3, has achieved a significant milestone in its global expansion strategy. The company has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its VITADEETM 100 SD product, a spray-dried variant of Vitamin D3.

Key Highlights

• Fermenta Biotech receives CEP for VITADEETM 100 SD from EDQM
• The certified product is manufactured at the company's Kullu, Himachal Pradesh facility
• Fermenta becomes one of only two companies globally to hold a CEP for this Vitamin D3 variant
• The certification reinforces the company's commitment to regulatory compliance and quality standards

Significance of the Certification

The CEP certification is a testament to Fermenta Biotech's adherence to stringent European Pharmacopoeial Standards for manufacturing and product quality. This approval enables the company to meet these high standards and enhances its position in the international health and nutrition industry.

Prashant Nagre, Managing Director of Fermenta Biotech, commented on the achievement: "As we enter our 75th year, receiving the CEP for VITADEE™ 100 SD marks a significant milestone for Fermenta. It reinforces our commitment to the benchmarks of regulatory compliance by growing our product portfolio whilst strengthening our position as an established global partner in the field of Vitamin D3."

Impact on Global Presence

The certification is expected to have a positive impact on Fermenta Biotech's international footprint. It allows the company to move further up the value chain and demonstrates its capability to deliver products that meet the highest global quality and regulatory standards.

About Fermenta Biotech Limited

Founded in 1951, Fermenta Biotech Limited has established itself as a pioneer in pharmaceutical and nutritional ingredients. The company's portfolio includes:

• Customized Premixes
• Fortified Rice Kernel (FRK)
• Other nutritional ingredients

Fermenta caters to over 400 customers across 60 countries, with applications in pharmaceuticals, dietary and nutritional supplements, food, animal nutrition, and rodenticides. The company operates manufacturing facilities in Kullu, Dahej, and Tirupati, all of which are certified by global accreditations.

This latest achievement underscores Fermenta Biotech's commitment to excellence, innovation, and trust in the global Vitamin D3 market, positioning the company for accelerated growth and expanded opportunities in the health and nutrition industry.

Fermenta Biotech Ltd , a leading manufacturer of Vitamin D3, has reported a significant turnaround in its financial performance for the fourth quarter of the fiscal year. The company's latest financial results showcase a remarkable improvement in both profitability and revenue.

Strong Financial Performance

Fermenta Biotech reported a consolidated net profit of ₹343.90 crore for the fourth quarter, marking a substantial recovery from a loss of ₹69.00 crore in the same period last year. This impressive turnaround demonstrates the company's ability to navigate challenges and improve its bottom line.

The company's revenue also saw a notable increase, rising to ₹1,400.00 crore in Q4, up from ₹973.00 crore in the corresponding quarter of the previous year. This represents a year-over-year growth of approximately 44%, indicating strong demand for the company's products and services.

Key Financial Highlights

Dividend Announcement

In a move that will likely please shareholders, Fermenta Biotech's board of directors has recommended a final dividend of ₹2.50 per equity share. This dividend announcement comes as a positive signal, reflecting the company's improved financial position and its commitment to returning value to shareholders.

Looking Ahead

While specific details about the factors driving Fermenta Biotech's improved performance are not available, the significant increase in both revenue and profitability suggests a combination of factors such as increased sales, potentially improved operational efficiency, and possibly favorable market conditions for its products.

As a key player in the Vitamin D3 market and with interests in biotechnology, Fermenta Biotech's strong quarterly results may indicate positive trends in these sectors. However, investors and market watchers will likely be keen to see if this performance can be sustained in the coming quarters.

The company's ability to turn a significant loss into a substantial profit within a year is noteworthy and may warrant attention from industry analysts and investors alike. As always, it's advisable for stakeholders to consider these results in the context of broader market trends and the company's long-term strategy.